King Pharmaceuticals submits NDA for SPECT imaging agent

12/19/2008 | PR-inside

King Pharmaceuticals has filed with the FDA a New Drug Application for its CorVue SPECT imaging agent as an adjunct to noninvasive myocardial perfusion imaging tests for patients with known or suspected coronary artery disease. CorVue offers "a safe and effective option to diagnose a disease that affects about one in three adults and is the leading cause of death in the U.S.," a company official said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations